Skip to main content
Top
Published in: Obesity Surgery 2/2012

01-02-2012 | Clinical Research

Clinical Predictors of Different Grades of Nonalcoholic Fatty Liver Disease

Authors: Wilson Salgado Júnior, Carla Barbosa Nonino-Borges

Published in: Obesity Surgery | Issue 2/2012

Login to get access

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is one of the comorbidities related to obesity. Liver biopsy has been used as the “gold standard” for the diagnosis, grading, and prognosis of obese patients. The objective of the present study was to evaluate clinical predictors of more advanced stages of NAFLD.

Methods

In this retrospective study we assessed several physical and laboratorial factors, including some cytokines, in morbidly obese patients submitted to Roux-en-Y gastric bypass that could be related to the diagnosis and staging of NAFLD. Fragments of the livers were obtained from wedge biopsies during operation.

Results

The medical records of 259 patients were studied. The patients were divided into four groups: normal hepatic biopsy, steatosis, mild nonalcoholic steatohepatitis (NASH), and moderate and severe NASH. There were no differences in cytokine levels among groups. The triglyceride levels were the only variable that could stratify the grades of NAFLD and also differentiate from normal livers in the female patients. Also in this group, the aminotransferases and GGT levels and fasting glucose were predictors of the more advanced stages of NASH, while BMI and weight were predictors of the more advanced stages of NASH in male patients.

Conclusions

There are no available markers in clinical practice to detect the initial stages of NAFLD. It is very important to perform a liver biopsy in all patients submitted to bariatric surgery and in obese patients with no indication to be operated in the presence of elevated blood levels of aminotransferases, GGT, and fasting glucose.
Literature
1.
go back to reference Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.PubMedCrossRef Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.PubMedCrossRef
2.
go back to reference Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221–31.CrossRef Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221–31.CrossRef
3.
go back to reference Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract & Resear Clin Gastroenterol. 2002;16:733–47.CrossRef Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract & Resear Clin Gastroenterol. 2002;16:733–47.CrossRef
4.
go back to reference Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–7.PubMedCrossRef Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042–7.PubMedCrossRef
5.
go back to reference Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–60.PubMedCrossRef Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–60.PubMedCrossRef
6.
go back to reference Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–9.PubMed Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107:1103–9.PubMed
7.
go back to reference Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY. 1990;11:74–80.PubMedCrossRef Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY. 1990;11:74–80.PubMedCrossRef
8.
go back to reference Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.PubMedCrossRef Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117–23.PubMedCrossRef
9.
go back to reference Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.PubMedCrossRef Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.PubMedCrossRef
10.
go back to reference Degertekin B, Ozenirler S, Elbeg S, Akyol G. The serum endothelin- 1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci. 2007;52(10):2622–8.PubMedCrossRef Degertekin B, Ozenirler S, Elbeg S, Akyol G. The serum endothelin- 1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci. 2007;52(10):2622–8.PubMedCrossRef
11.
go back to reference Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25(4):779–86.PubMedCrossRef Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int. 2005;25(4):779–86.PubMedCrossRef
12.
go back to reference Wieckowska A, Zein NN, Yerian LM, López AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.PubMedCrossRef Wieckowska A, Zein NN, Yerian LM, López AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.PubMedCrossRef
13.
go back to reference Kukla M, Korczala KZ, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2010;45:235–42.PubMedCrossRef Kukla M, Korczala KZ, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2010;45:235–42.PubMedCrossRef
14.
go back to reference Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371–8.PubMedCrossRef Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008;40(5):371–8.PubMedCrossRef
15.
go back to reference Saadeh S, Younosi ZM, Rener EM, et al. The utility of radiological imaging in nonalcoholic fatty liver desease. Gastroenterology. 2002;123:745–50.PubMedCrossRef Saadeh S, Younosi ZM, Rener EM, et al. The utility of radiological imaging in nonalcoholic fatty liver desease. Gastroenterology. 2002;123:745–50.PubMedCrossRef
16.
go back to reference Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15:539–43.PubMed Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003;15:539–43.PubMed
17.
go back to reference Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.PubMedCrossRef Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.PubMedCrossRef
18.
go back to reference Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.PubMedCrossRef Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–7.PubMedCrossRef
19.
go back to reference Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916–23.PubMedCrossRef Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916–23.PubMedCrossRef
Metadata
Title
Clinical Predictors of Different Grades of Nonalcoholic Fatty Liver Disease
Authors
Wilson Salgado Júnior
Carla Barbosa Nonino-Borges
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 2/2012
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-011-0438-6

Other articles of this Issue 2/2012

Obesity Surgery 2/2012 Go to the issue